eFFECTOR Therapeutics, Inc. (EFTR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Stephen T. Worland Ph.D. | CEO, President & Director | 873.96k | -- | 1958 |
| Mr. Michael Byrnes M.B.A. | Chief Financial Officer | 654.82k | -- | 1977 |
| Dr. Douglas Warner M.D. | Chief Medical Officer | 660.16k | -- | 1972 |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | -- | -- | -- |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | -- | -- | -- |
eFFECTOR Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Corporate Governance
Recent Events
- Apr 16, 2024PRE 14A: Proxy StatementsSee Full Filing
- Apr 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 29, 2024POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingSee Full Filing
- Mar 28, 2024S-8: Offering RegistrationsSee Full Filing
- Mar 26, 202410-K: Periodic Financial ReportsSee Full Filing